Squamous Cell Carcinoma of the Head and Neck (SCCHN)
12
0
0
7
Key Insights
Highlights
Success Rate
58% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
41.7%
5 terminated out of 12 trials
58.3%
-28.2% vs benchmark
0%
0 trials in Phase 3/4
100%
7 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (12)
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
Study of INCA 0186 in Subjects With Advanced Solid Tumors
Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Study of PX-866 and Docetaxel in Solid Tumors
Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck